全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

245例消化系统神经内分泌肿瘤的内镜表现及病理特征分析
Endoscopic Manifestations and Pathological Features of 245 Cases of Neuroendocrine Tumors in the Digestive System

DOI: 10.12677/ACM.2020.1011369, PP. 2444-2450

Keywords: 神经内分泌肿瘤,消化系统,流行病学,内镜表现,病理特征
Neuroendocrine Tumor
, Digestive System, Epidemiology, Endoscopic Manifestations, Pathological Features

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:探讨消化系统神经内分泌肿瘤(Neuroendocrine tumors, NETs)的流行病学、内镜表现及临床病理特征,以提高对该类疾病的诊治水平。方法:回顾性分析青岛大学附属医院消化内科自2013年2月至2020年9月诊断为NETs患者的临床资料,探讨其流行病学、内镜表现及临床病理特征。结果:共检出消化系统NETs患者245例,男性130例(53.1%),女性115例(46.9%),平均年龄(53.3 ± 12.3)岁。消化系统NETs好发部位以结直肠(127例,51.8%)和胃(81例,33.1%)最常见。肿瘤直径 ≤ 10.0 mm的患者有209例(85.3%);10.0~20.0 mm25例(10.2%);>20.0 mm 11例(4.5%)。病变多起源于黏膜肌层(55.4%)及黏膜下层(43.8%)。根据WHO分类标准,245例患者病理分期为NETG1的有204例(83.3%);NETG2的有40例(16.3%);NEC的有1例(0.4%)。免疫组化染色结果显示,Syn阳性率为95.1%,CgA阳性率为55.1%。上消化道与下消化道NETs在性别(P = 0.001)、肿瘤大小(P < 0.001)及病理分型(P < 0.001)存在统计学差异。结论:消化系统NETs的好发部位以结直肠和胃最常见。肿瘤直径绝大多数不超过10.0 mm,病变多起源于黏膜肌层及黏膜下层。ESD是既安全又有效的微创治疗方法。超声内镜对消化系统NETs具有较大的诊断价值。
Objective: To investigate the epidemiology, endoscopic manifestations and clinicopathological features of neuroendocrine tumors of the digestive system in order to improve the diagnosis and treatment of these diseases. Method: The clinical data of NETs patients diagnosed in department of Gastroenterology, Affiliated Hospital of Qingdao University from February 2013 to September 2020 were retrospectively analyzed to investigate the epidemiology, endoscopic manifestations and clinicopathological features. Results: A total of 245 patients with digestive NETs were detected, including 130 males (53.1%) and 115 females (46.9%), with an average age of 53.3 ± 12.3 years. The most common sites of gastrointestinal NETs were the colorectal (127 cases, 51.8%) and the stomach (81 cases, 33.1%). There were 209 patients (85.3%) with tumor diameter ≤ 10.0 mm. 25 patients (10.2%) with tumor diameter between 10.0 - 20.0 mm; 11 patients (4.5%) with tumor diameter > 20.0 mm. The tumor mostly originated in the muscularis mucosa (55.4%) and submucosa (43.8%). According to WHO classification criteria, 204 (83.3%) of 245 patients were diagnosed as NETG1 in pathological stage; 40 (16.3%) patients were diagnosed as NETG2; and only 1 (0.4%) patient were in NEC. The immunohistochemical staining results showed that the positive rate of Syn and CgA were 95.1% and 55.1% respectively. There were statistically significant differences between upper and lower gastrointestinal NETs in gender (P = 0.001), tumor size (P < 0.001), and pathological type (P < 0.001). Conclusion: Colorectal and stomach are the most common sites of gastrointestinal NETs. Most of the tumors are no more than 10.0 mm in diameter, and most of the lesions originate from the mucosal musculus and submucosa. ESD is a safe and effective minimally invasive treatment. Endoscopic ultrasonography is of great diagnostic value for NETs

References

[1]  Oberg, K. (2010) Neuroendocrine Tumors (NETs): Historical Overview and Epidemiology. Tumori, 96, 797-801.
https://doi.org/10.1177/030089161009600530
[2]  Caplin, M.E., Baudin, E., Ferolla, P., et al. (2015) Pulmonary Neuroendocrine (Carcinoid) Tumors: European Neuroendocrine Tumor Society Expert Consensus and Recommendations for Best Practice for Typical and Atypical Pulmonary Carcinoids. Annals of Oncology, 26, 1604-1620.
https://doi.org/10.1093/annonc/mdv041
[3]  Fitzgerald, T.L., Dennis, S.O., Kachare, S.D., et al. (2015) Increasing Incidence of Duodenal Neuroendocrine Tumors: Incidental Discovery of Indolent Disease? Surgery, 158, 466-471.
https://doi.org/10.1016/j.surg.2015.03.042
[4]  王霄, 宋争放, 姚文秀, 等. 胃肠胰神经内分泌瘤的临床病理特点及预后的多因素分析[J]. 中华医学杂志, 2013, 93(18): 1411-1414.
[5]  Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncology, 3, 1335-1342.
https://doi.org/10.1001/jamaoncol.2017.0589
[6]  李增山. 胃肠胰神经内分泌肿瘤分类及病理学进展[J]. 浙江大学学报(医学版), 2016, 45(1): 10-23.
[7]  Vinik, A.I., Woltering, E.A., Warner, R.R., et al. (2010) NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor. Pancreas, 39, 713-734.
https://doi.org/10.1097/MPA.0b013e3181ebaffd
[8]  Nagtegaal, I.D., Odze, R.D., Klimstra, D., et al. (2020) The 2019 WHO Classification of Tumours of the Digestive System. Histopathology, 76, 182-188.
https://doi.org/10.1111/his.13975
[9]  Yao, J.C., Hassan, M., Phan, A., et al. (2008) One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology, 26, 3063-3072.
https://doi.org/10.1200/JCO.2007.15.4377
[10]  Desserud, K.F., Bukholm, I. and S?reide, J.A. (2017) Compensation Claims for Sub-Substandard Care of Patients with Gastroentero-Pancreatic Neuroendocrine Tumors: A Nationwide Descriptive Study of Cases between 2005-2016 in Norway. Anticancer Research, 37, 5667-5671.
https://doi.org/10.21873/anticanres.12002
[11]  Russolillo, N., Vigano, L., Razzore, P., et al. (2015) Survival Prognostic Factors of Gastro-Enteric-Pancreatic Neuroendocrine Tumors after Primary Tumor Resection in a Single Tertiary Center: Comparison of Gastro-Enteric and Pancreatic Locations. European Journal of Surgical Oncology, 41, 751-757.
https://doi.org/10.1016/j.ejso.2015.02.011
[12]  Al-Risi, E.S., Al-Essry, F.S. and Mula-Abed, W.S. (2017) Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman. Oman Medical Journal, 32, 365-370.
https://doi.org/10.5001/omj.2017.71
[13]  郭林杰, 唐承薇. 中国胃肠胰神经内分泌肿瘤临床研究现状分析[J]. 胃肠病学, 2012, 17(5): 276-278.
[14]  高尤亮, 王晨, 曾德华, 等. 神经内分泌肿瘤714例临床病理分析[J]. 海南医学, 2013, 24(2): 285-287.
[15]  Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., et al. (2010) Incidence, Patterns of Care and Prognostic Factors for Outcome of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Annals of Oncology, 21, 1794-1803.
https://doi.org/10.1093/annonc/mdq022
[16]  苏惠, 李娜, 王海红, 等. 167例胃肠道神经内分泌肿瘤的内镜表现及病理特征回顾性分析[J]. 胃肠病学和肝病学杂志, 2019, 28(4): 405-409.
[17]  Rindi, G., Bordi, C., La Rosa, S., et al. (2011) Gastroenteropancreatic (Neuro)endocrine Neoplasms: The Histology Report. Digestive and Liver Disease, 43, S356-S360.
https://doi.org/10.1016/S1590-8658(11)60591-4
[18]  Osamura, R.Y. (2014) Current Concept of Neuroendocrine Tumors (NET): Its Changes for the Past 20 Years. Pathology, 46, S1.
https://doi.org/10.1097/01.PAT.0000454055.93030.32
[19]  Uccella, S., Sessa, F. and La Rosa, S. (2015) Diagnostic Approach to Neuroendocrine Neoplasms of the Gastrointestinal Tract and Pancreas. Turk Patoloji Dergisi, 31, 113-127.
https://doi.org/10.5146/tjpath.2015.01319
[20]  顾健, 焦宇飞. 胃肠胰神经内分泌肿瘤病理学特征与分级[J]. 现代肿瘤医学, 2106, 24(16): 2648-2651.
[21]  Fan, J.-G., Kim, S.-U. and Wong, V.W.-S. (2017) New Trends on Obesity and NAFLD in Asia. Journal of Hepatology, 67, 862-873.
https://doi.org/10.1016/j.jhep.2017.06.003
[22]  Yazici, C. and Boulay, B.R. (2017) Evolving Role of the Endoscopist in Management of Gastrointestinal Neuroendocrine Tumors. World Journal of Gastroenterology, 27, 4847-4855.
https://doi.org/10.3748/wjg.v23.i27.4847
[23]  He, L., Deng,, T. and Luo, H.S. (2015) Efficacy and Safety of Endoscopic Resection Therapies for Rectal Carcinoid Tumors: A Meta-Analysis. Yonsei Medical Journal, 56, 72-81.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133